Jianmin Fang

Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model

Jianmin Fang, Yuen Shing, Dmitri Wiederschain et al. · Proceedings of the National Academy of Sciences · 2000 · 392 citations

Medicine, Oncology, Pathology +15

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang et al. · Clinical Cancer Research · 2020 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Zhi Peng, Tianshu Liu, Jia Wei et al. · Cancer Communications · 2021 · 202 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

Jicheng Lv, Lijun Liu, Chuan‐Ming Hao et al. · Kidney International Reports · 2022 · 185 citations · Full text

Medicine, Nephrology, Pharmacotherapy +12

Identification of Drosophila melanogaster yellow-f and yellow-f2 proteins as dopachrome-conversion enzymes

Qian Han, Jianmin Fang, Haizhen Ding et al. · Biochemical Journal · 2002 · 183 citations · Full text

Life Sciences, Entomology, Molecular Biology +13